MEIS1 and leukemia: In NUP98‐r, KMT2A‐r, and NPM1‐mutant leukemia, all of which induce and depend on the MEIS1/HOXA transcriptional program, small molecule inhibitors that disrupt the Menin‐KMT2A interaction have demonstrated potent antileukemic effects.116, 136, 158